Scher HI - Search Results

1

The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.

Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW. Chakraborty G, et al. Among authors: scher hi. Clin Cancer Res. 2022 Aug 15;28(16):3603-3617. doi: 10.1158/1078-0432.CCR-21-4272. Clin Cancer Res. 2022. PMID: 35670774 Free PMC article.

2

Chemotherapy for muscle-infiltrating bladder cancer.

Scher HI, Kantoff PW. Scher HI, et al. Hematol Oncol Clin North Am. 1992 Feb;6(1):169-78. Hematol Oncol Clin North Am. 1992. PMID: 1556048 Review.

3

Chemotherapy for metastatic bladder cancer.

Kantoff PW, Scher HI. Kantoff PW, et al. Among authors: scher hi. Hematol Oncol Clin North Am. 1992 Feb;6(1):195-203. Hematol Oncol Clin North Am. 1992. PMID: 1556050 Review.

4

Introduction: prostate cancer.

Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):511-3. Semin Oncol. 1994. PMID: 7939744 No abstract available.

5

Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.

Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Ghossein RA, et al. Among authors: scher hi. Urology. 1997 Jul;50(1):100-5. doi: 10.1016/S0090-4295(97)00127-1. Urology. 1997. PMID: 9218026

6

Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.

Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Zhang S, et al. Among authors: scher hi. Clin Cancer Res. 1998 Feb;4(2):295-302. Clin Cancer Res. 1998. PMID: 9516914

7

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L, Schlom J, Larson SM. Slovin SF, et al. Among authors: scher hi. Clin Cancer Res. 1998 Mar;4(3):643-51. Clin Cancer Res. 1998. PMID: 9533532

8

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. Imbriaco M, et al. Among authors: scher hi. Clin Cancer Res. 1998 Jul;4(7):1765-72. Clin Cancer Res. 1998. PMID: 9676853

9

Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal.

Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Agus DB, et al. Among authors: scher hi. Cancer Res. 1998 Jul 15;58(14):3009-14. Cancer Res. 1998. PMID: 9679964

10

Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.

Engelhardt M, Albanell J, Drullinsky P, Han W, Guillem J, Scher HI, Reuter V, Moore MA. Engelhardt M, et al. Among authors: scher hi. Clin Cancer Res. 1997 Oct;3(10):1849-57. Clin Cancer Res. 1997. PMID: 9815573

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

685 results

Search Page